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Abstract
Background: Migraine with aura (MA) is a subtype of typical migraine. Migraine with aura (MA)
also encompasses a rare severe subtype Familial Hemiplegic Migraine (FHM) with several known
genetic loci. The type 2 FHM (FHM-2) susceptibility locus maps to chromosome 1q23 and
mutations in the ATP1A2 gene at this site have recently been implicated. We have previously
provided evidence of linkage of typical migraine (predominantly MA) to microsatellite markers on
chromosome 1, in the 1q31 and 1q23 regions. In this study, we have undertaken a large genomic
investigation involving candidate genes that lie within the chromosome 1q23 and 1q31 regions using
an association analysis approach.
Methods: We have genotyped a large population of case-controls (243 unrelated Caucasian
migraineurs versus 243 controls) examining a set of 5 single nucleotide polymorphisms (SNPs) and
the Fas Ligand dinucleotide repeat marker, located within the chromosome 1q23 and 1q31 regions.
Results: Several genes have been studied including membrane protein (ATP 1 subtype A4 and
FasL), cytoplasmic glycoprotein (CASQ 1) genes and potassium (KCN J9 and KCN J10) and calcium
(CACNA1E) channel genes in 243 migraineurs (including 85% MA and 15% of migraine without
aura (MO)) and 243 matched controls. After correction for multiple testing, chi-square results
showed non-significant P values (P > 0.008) across all SNPs (and a CA repeat) tested in these
different genes, however results with the KCN J10 marker gave interesting results (P = 0.02) that
may be worth exploring further in other populations.
Conclusion: These results do not show a significant role for the tested candidate gene variants
and also do not support the hypothesis that a common chromosome 1 defective gene influences
both FHM and the more common forms of migraine.
Background
Migraine with aura (MA) is defined as the more severe
subtype of typical migraine and is associated with focal
neurological symptoms such as altered vision accompany-
ing the usual symptoms of migraine [1]. Migraine with
aura (MA) also contains a rare severe subtype of Familial
Hemiplegic Migraine (FHM), which is accompanied by
migraine headache and quite severe associated neurologi-
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locus maps to chromosome 1q23 and mutations in the
ATP1A2 gene at this site have recently been implicated in
two FHM pedigrees not showing linkage to the FHM-1
locus on chromosome 19p13 [2]. We have previously pro-
vided evidence of linkage to microsatellite markers on
chromosome 1 showing evidence of linkage to chromo-
some 1q31 (C1q31) [3] and also evidence of excess allele
sharing in predominantly MA affected pedigrees to the
C1q23 genomic region [4]. We have previously also inves-
tigated the FHM-2 (ATP1A2) gene located at C1q23
through mutation analysis but found no link between this
gene and the common forms of migraine [4].
To further investigate a potential chromosome 1q involve-
ment in migraine, we undertook association analysis of
other potential candidate genes that lie within the 1q23
and 1q31 regions on chromosome 1. These include a sub-
unit of the sodium/potassium ATPase, ATP1A4, an inte-
gral membrane protein catalytic subunit directly
responsible for ion transport such as the active transport
of sodium ions in exchange for potassium ions across cell
membranes. The electrochemical gradient generated by
this exchange is essential for maintaining membrane
potentials and for sodium – coupled co-transport of a
variety of organic and inorganic molecules [5]. Another
gene tested was CASQ1 (Human fast-twitch skeletal
Calsequestrin 1), an acid glycoprotein believed to func-
tion as a storage protein for calcium in the sarcoplasmic
reticulum [6]. This protein binds calcium ions with a high
capacity but with a moderate affinity and consequently is
able to modulate activity of the ryanodine receptor, con-
trolling muscle calcium homeostasis and thus excitation-
contraction coupling [7]. Furthermore, CASQ 1 can regu-
late the GATA 4-and AP-1-dependent transcriptional
events, indicating the existence of sarcoplasmic reticulum
nuclear circuits of signal transduction in adult cardiac
muscle [8]. Several cardiac disorders notably some con-
genital heart defects, such as those affecting the patent
foramen oval have recently been reported to be comorbid
with migraine [9], suggesting a potential common genetic
component in these disorders.
Channel mutations or "channelopathies" are increasingly
found to be the cause of various neurological disorders in
humans [10]. The KCN channels (potassium inwardly-
rectifying channel) participate in polarisation of neuronal
membrane and the regulation of the action potential,
whereby they control neuronal excitability. In this study,
the human KCNJ9 and KCNJ10 genes (potassium
inwardly-rectifying channel, subfamily J, member 9 and
10) were also investigated. They are members of the G-
protein-activated inwardly rectifying potassium (K+)
(GIRK) channel family responsible for playing a critical
inhibitory role in K+transport throughout the nervous sys-
tem, heart, pancreas, brain and kidney [11]. These chan-
nels have widespread expression in the central nervous
system, helping to regulate extracellular K+ ion concentra-
tions.
We also investigated a CA repeat polymorphism localized
46-kb upstream of the Fas ligand gene (FasL) gene on
C1q23. FasL is a transmembrane protein belonging to the
tumor necrosis family (TNF, member 6). It is an apoptosis
inducing T-cell effector predominantly expressed in acti-
vated T lymphocytes, in natural killer cells and in immune
privileged sites, such as the testes and eye [12]. FasL is also
involved in vascular smooth muscle cell apoptosis, which
part of atherosclerotic plaque rupture causing myocardial
infarction [13].
Finally, the CACNA1E gene on C1q31 was also tested.
This is a second region of interest on C1 for typical
migraine, as previous results from our laboratory have
also shown linkage to this region [3]. CACNA1E is the
alpha 1E subunit of R-type voltage-dependent calcium
channels. Notably CACNA1A, the alpha 1A subunit at
C19p13 has been implicated in FHM-1 [14]. These subu-
nits form voltage-sensitive calcium channels (VSCC),
which mediate the entry of calcium ions into excitable
cells. They are also involved in a variety of calcium-
dependent processes, including muscle contraction, hor-
mone or neurotransmitter release, gene expression, cell
motility, cell division and cell death. Calcium channels
containing alpha-1E subunit could be involved in the
modulation of firing patterns of neurons which is impor-
tant for information processing.
Overall this study investigated six genes localized to the
chromosome 1q23 and 1q31 regions, five of which con-
tain informative SNPs and one dinucleotide repeat
upstream from the FasL gene. The population utilized was
a large case-control migraine population – age, sex and
ethnically matched.
Methods
SNP and dinucleotide polymorphism selection
This study incorporated analysis of a CA dinucleotide
repeat polymorphism located 46-kb upstream from the
Fas ligand gene (FasL) and also SNP analysis techniques
for variants within other candidate genes on chromosome
1q23 and 1q31. SNPs were selected using SNPbrowser™
Software (ABI), Ensembl Genome Browser and NCBI SNP
databases. A detailed summary of all variants selected for
this study is displayed in Table 1.
PCR conditions
Primer sequences for each SNP and the dinucleotide
repeat were designed by utilizing Primer Express™ v 2.0
software (ABI) or obtained from previous publicationsPage 2 of 8
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and the FasL marker utilized final concentrations of
MgCl2,Primers, dNTPs, 10 × Buffer and Taq polymerase
with 1.75 mM, 0.2 μM, 200 μM, 1 × and 1U respectively.
Approximately 40 ng of DNA per reaction was used in the
PCR. Cycling conditions for ATP1A4 and CASQ1 SNPs
consisted of 94°C for 4 minutes, then 35 cycles of 94°C
for 1 minute, 55°C for 1 minute and 72°C for 30 seconds.
The final PCR extension consisted of 72°C for 2 minutes.
For KCNJ10 an annealing temperature of 57°C was
needed while the FasL marker and CACNA1E SNP utilized
a 35 cycle – 60°C annealing step without an extension
step incorporated.
Genotyping analysis and Restriction Digest conditions
The FasL dinucleotide repeat marker was labelled with
FAM fluorescent dye label and following PCR loaded on
an ABI310™ Genetic Analyser with Genescan Analysis™
3.1 software. Genotyping was performed with ABI Geno-
typer™ 2.1 software.
SNP analysis was performed using restriction enzyme sites
overlapping the SNP in question. Digest conditions for all
SNPs utilized 10 ul of PCR product and a 10 ul mix of 3U
of restriction enzyme with 1 × enzyme buffer and H2O.
Digest products were loaded and electrophoresed on 3–
4% high resolution agarose gels whereby genotyping was
performed.
Statistical data analysis
Genotype and allele frequencies for all SNP variants and
the CA repeat were calculated from observed genotype
counts. As a statistical control for systematic genotyping
error and population stratification, the expected genotype
proportions according to the Hardy-Weinberg law were
calculated and compared to observed genotypes. Geno-
type and allele frequencies were initially assessed for asso-
ciation with migraine, then MA and MO subpopulations
were assessed, using conventional contingency table anal-
yses incorporating the standard chi-squared test for inde-
pendence. Genetic risk magnitudes (effect size) were
Table 2: Primer sequences utilized for SNP and CA polymorphism PCR amplication
Ref SNP ID GENE Recombination mapping 
position
Sequence 5'->3'
rs1130183 KCNJ10 155.96 – 156.04 cM F-GCAAGCCCTGCCTCATGA and R-
AGGGCATTGGAAGAGAGG
rs2494211 KCNJ9 156.05 – 156.08 cM F-CAGGCACAGGCAGGAAGAG and R-
GTGATTCCAACGCACACTGG
rs6427504 ATP1A4 156.13 – 156.17 cM F-GCTCCAAATGTCAGGTTCCC and R-
GAGTGCTAGGCTGCTGAGCA
rs3747623 CASQ1 156.16 – 156.20 cM F-CCCCTAGGCTTAATCCAGGG and R-
GGGCAGGCAGTGGAGTTTT
Nil FasL (CA Rpt) 174.93 – 174.95 cM F-ACCATTTCACTCACACACAAC and R-
GGTAAGGGAAGCACAATAACTG
rs704326 CACNA1E 181.83 – 182.42 cM F-CCTCATTACCTCTGGATTTGACATT and R-
CATTCACCAGAGACTGCCGTT
Positioning of genes (cM) based on NCBI Map Viewer using 'deCODE' and 'Genes On Sequence' mapping data
Table 1: A detailed summary of all variants selected for this study
GENE Ref SNP 
ID
Chromos
ome 
location
Coding Alleles Translati
on
AA 
change
Minor 
allele 
freq
Restricti
on 
enzyme
Restricti
on site
RE 
Digest 
fragemen
t (bp)
KCNJ10 rs1130183 C1q23.2 yes, exon2 C/T non-syn Arg-Cys T = 0.0240 Ear I CTCTTC 614,376,23
8,8
KCNJ9 rs2494211 C1q23.2 no,3'-UTR T/C Nil nil C = 0.28 Rsa I GTAC 382,204,17
8
ATP1A4 rs6427504 C1q23.3 yes, exon3 T/C non-syn Gly-Asp C = 0.337 Bcc I CCATC 365,249,11
6
CASQ1 rs3747623 C1q23.3 no, intron3 T/C nil nil C = 0.481 Hph I TCACC 245,189,11
6,56
CACNA1E rs704326 C1q25.3 yes, 
exon43
G/A non-syn Ala-Thr G = 0.390 AciI CCGC 153,109,44
FasL nil C1q25.2 No,3'-UTR CA rpt nilPage 3 of 8
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vals.
In total, we investigated the six DNA markers in controls
and case groups of the population (MA, MO, Migraine
(MO+MA)). Therefore, the standard significance level of 5
% has been adjusted to α = 0.05/6 = 0.008, according the
application of Bonferroni correction for multiple testing,
to provide evidence for association of the studied poly-
morphisms with migraine susceptibility.
Subjects
A cross-sectional association approach was employed, uti-
lizing genomic DNA samples obtained from 243 migraine
affected individuals and 243 controls. The populations
consisted of Caucasians from general Australian Commu-
nity. To minimize potential bias from population stratifi-
cation, the control group was matched for sex, age (+/- 5
years) and ethnicity. Migraine patients were clinically
defined and suitably matched non-migraine individuals
were obtained for the control population. The subjects
were diagnosed for migraine using a detailed question-
naire and clinical neurologist (JM) in accordance with the
International Headache Society criteria [1]. The blood
samples obtained from patients were collected through
the Genomics Research Centre patient clinic and purified
DNA from these samples was obtained using standard
extraction methods [15].
Individuals were grouped together as total migraine
affected, containing both MA and MO diagnosed samples.
For further statistical analysis the groups were then split
into migraine with aura and migraine without aura popu-
lations. The control population consisted of non-
migraine affected individuals.
Ethical approval
This research was reviewed and approved by the Griffith
University Human Research Ethics Committee (ethics
protocol numberMSC/05/05/HREC) and all subjects par-
ticipating in the study gave informed consent.
Results
Six markers localised to the C1q23-C1q31 region covering
several genes of interest (ATP1A4, CASQ1, KCNJ9 and
J10, FasL and CACNA1E), have been analysed in regard to
their potential association with migraine in a large popu-
lation (243 migraineurs versus 243 healthy individuals).
The distribution of all genotypes of the variants in the
studied population did not deviate significantly from
Hardy-Weinberg Equilibrium (P > 0.05).
Table 3 represents the results of the allelic and genotypic
frequency distribution of the studied SNPs. Results
showed no significant difference between controls and
migraine patients for the allelic frequencies (χ2 = 1.59, 2
df, P = 0.207; χ2 = 0.46, 2 df, P = 0.713; χ2 = 1.06, 2 df, P
= 0.496; χ2 = 0.14, 2 df, P = 0.303; χ2 = 1.00, 2 df, P = 0.6
respectively for ATP1A4, CASQ1, KCNJ9, KCNJ10 and
CACNA1E). Also there was no significant association for
the genotypic frequencies between controls and migraine
for any of the studied polymorphisms (P > 0.008), taking
into account the Bonferroni corrected significance level (α
= 0.008) (Table 3). Stratified analyses of migraine sub-
types did not indicate any association specifically attrib-
uted to the MA or MO subtype group for both allelic and
genotypic frequencies of all the five studied SNPs (P >
0.008), as shown in Table 3. Results from KCNJ10 marker
however did show an interesting result for genotypic anal-
ysis (χ2 = 7.65, P = 0.02) but there were very low numbers
in some of genotype groups, and a larger population
would be needed to assess these variations more appropri-
ately (Table 4). When the results were analysed by gender
and by subtype of migraine, no significant association was
observed for KCNJ10 genotype and allelic distribution
(Table 4).
As shown in Table 5, the frequencies of the two major alle-
les of the FasL CA repeat (alleles, 3 and 4), were found to
make up nearly 99 % of the alleles in both the control and
migraineur groups. This finding is similar to that reported
by Zayas et al. (2001) in 139 unrelated healthy individu-
als. Results for the marker showed no significant differ-
ence for the FasL polymorphism in controls versus MA,
MO or combined (MA+ MO) groups (χ2 = 5.93, 4 df, P =
0.204; χ2 = 7.55, 4 df, P = 0.109; χ2 = 0.94, 4 df, P = 0.919,
respectively).
Discussion
The C1q23 region covers a large genetic distance of 1–3
cytogenetic bands, is greater than 12 MB in length and
contains a high density of genes in this particular region.
Since the discovery of FHM-2 [2], a disorder caused by
mutations in the ATP1A2 gene at the C1q23 locus, this
region has been the focus of intense genetic research for
the more common types of migraine. Research on
migraine is not only of interest at this locus, other genetic
diseases and neurological conditions have also been asso-
ciated with this region. Family linkage studies conducted
by Gardner et al. originally implicated an additional FHM
susceptibility locus within a broad region (44 cM) on
chromosome 1q31 [16]. Independent research carried out
by Ducros et al. indicated a second FHM locus at 1q21-23,
approximately 30 cM centromeric to the region reported
by Gardner et al [17]. Further investigation of these FHM
susceptibility regions has subsequently implicated a spe-
cific ATPase gene ATP1A2 on chromosome 1q23. The
gene has been identified as having causal mutations in
some FHM pedigrees with the locus now defined as
FHM2. This region as well as the 1q31 region may also bePage 4 of 8
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N Alleles Genotypes
Group (alleles) C T CC CT TT
ATP 1A4 SNP rs 6427504
Migraine 466 167 (35.8%) 299 (64.2%) 30 (12.9%) 107 (45.9%) 96 (41.2%)
Male 64 22 (34.4%) 42 (65.6%) 4 (12.5%) 14 (43.8%) 14 (43.8 %)
Female 402 145 (36.1%) 257 (63.9%) 26 (12.9%) 93 (46.3%) 82 (40.8%)
MA 382 139 (36.4%) 243 (63.6%) 24 (12.6%) 91 (47.6%) 76 (39.8%)
MO 74 26 (35.1%) 48 (64.9%) 5 (13.6%) 16 (43.2%) 16 (43.2%)
Control 416 167 (40%) 251 (60%) 38 (18.2%) 91 (43.5%) 80 (38.3%)
Male 66 25 (37.9%) 41 (62.1%) 5 (15.2%) 15 (45.5%) 13 (39.3%)
Female 352 142 (40.3%) 210 (59.7%) 33 (18.8%) 76 (43.1 %) 67 (38.1%)
Total case vs con-
trol
X2 = 1.59 P = 0.207 X2 = 2.39 P = 0.302
Subtype MA vs cont: X2 = 1.07 P = 0.30 X2 = 2.46 P = 0.29
Subtype MO vs cont X2= 0.61 P = 0.43 X2 = 0.59 P = 0.74
N Alleles Genotypes
Group (alleles) C T CC CT TT
CAS Q1 SNP rs 3747623
Migraine 446 288 (63.2%) 168 (36.8%) 93 (40.8%) 102 (44.7%) 33 (14.5%)
Male 68 45 (66.2%) 23 (33.8%) 16 (47.1%) 13 (38.2%) 5 (14.7 %)
Female 388 243 (62.6%) 145 (37.4%) 77 (39.7%) 89 (45.9%) 28 (14.4%)
MA 376 235 (62.5%) 141 (37.5%) 76 (40.4%) 83 (44.1%) 29 (15.4%)
MO 66 42 (63.6%) 24 (36.4%) 12 (36.4%) 18 (54.3%) 3 (9.1%)
Control 430 281 (65.3%) 149 (34.7%) 89 (41.4%) 103 (47.9%) 23 (10.7%)
Male 66 38 (59.4%) 26 (40.6%) 11 (34.4%) 16 (50%) 5 (15.6%)
Female 352 243 (66.4%) 123 (33.6%) 78(47.1%) 87 (38.2 %) 18 (14.7%)
Total case vs con-
trol
X2 = 0.46 P = 0.496 X2 = 1.48 P = 0.473
Subtype MA vs cont: X2 = 0.71 P = 0.40 X2 = 2.07 P = 0.36
Subtype MO vs cont X2 = 0.07 P = 0.78 X2 = 0.51 P = 0.77
N Alleles Genotypes
Group (alleles) C T CC CT TT
KCNJ9 SNP rs 2494211
Migraine 466 322 (66.5%) 162 (33.5%) 113 (46.7%) 96 (39.7%) 33 (13.6%)
Male 70 41 (58.6%) 29 (41.4%) 12 (34.3%) 17 (48.6%) 6 (17.1 %)
Female 414 281 (67.9%) 133 (32.1%) 101 (48.8%) 79 (38.2%) 27 (13%)
MA 392 262 (66.8%) 130 (33.2%) 94 (48%) 74 (37.8%) 28 (14.2%)
MO 74 48 (64.9%) 26 (35.1%) 15 (40.5%) 18 (48.6%) 4 (10.9%)
Control 486 308 (63.4%) 178 (36.6%) 95 (39.1%) 118 (48.6%) 30 (12.3%)
Male 70 41 (58.6%) 29 (41.4%) 11 (31.4%) 19 (54.3%) 5 (14.3%)
Female 416 267 (64.2%) 149 (35.8%) 84 (40.4%) 99 (47.6 %) 25 (12%)
Total case vs con-
trol
X2 = 1.06 P = 0.303 X2 = 3.96 P = 0.138
Subtype MA vs cont: X2 = 1.14 P = 0.28 X2 = 5.19 P = 0.07
Subtype MO vs cont X2 = 0.06 P = 0.80 X2 = 0.08 P = 0.96
N Alleles Genotypes
Group (alleles) C T CC CT TT
KCNJ10 SNP rs1130183
Migraine 440 408 (92.7%) 32 (7.3%) 189 (85.9%) 30 (13.6%) 1 (0.5%)
Male 66 59 (89.4%) 7 (10.6%) 26 (78.8%) 7 (21.2%) 0
Female 374 349 (93.3%) 25 (6.7%) 163 (87.2%) 23 (12.3%) 1 (0.5%)
MA 356 332 (93.3%) 24 (6.7%) 155 (87.1%) 22 (12.4%) 1 (0.6%)
MO 66 63 (95.5%) 3 (4.5%) 30 (90.9%) 3 (9.1%) 0
Control 422 394 (93.4%) 28 (6.6%) 189 (89.6%) 16 (7.6%) 6 (2.8%)
Male 62 57 (91.9%) 5 (8.1%) 27 (87.1%) 3 (9.7%) 1 (3.2%)
Female 360 337 (93.6%) 23 (6.4%) 162 (90%) 13 (7.2 %) 5 (2.8%)Page 5 of 8
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1q31 may also be implicated in MO or MA susceptibility
in a 82 independent pedigrees [3]. This study investigated
markers within both regions 1q23 and 1q31 for involve-
ment in typical migraine. We tested polymorphisms from
the KCNJ9, KCNJ10 and FasL genes (markers that had pre-
viously been tested in a number of other genetic disorders,
including Multiple Sclerosis (MS) [18]).
The CA repeat polymorphism located, upstream of the
FasL gene, has previously been found to be associated
with MS, in Spanish and American populations [18]. In
this study, as well as ours, Zayas et al, 2001 found that the
polymorphism consisted of two main alleles, 14 (allele A)
and 13 (allele B) repeats, with three others of 11, 12 and
15 repeats having a minor allele frequencies of < 1% in the
populations [18]. Therefore the two main alleles were
investigated in the multiple sclerosis study as well as in
this migraine study. From their results, Zayas et al, 2001
[18] suggested that chromosomes with the B allele have a
genetic background that reduces susceptibility to MS. In
this report, the CA repeat polymorphism (FasL) showed
no significant difference between control and migraine
groups (nor for any subtype of migraine, P > 0.05). The
FasL gene encodes a protein FasL, which interacts with a
transmembrane protein of the tumor necrosis factor
receptor superfamily to induce apoptosis in susceptible
cells [19]. Neuronal apoptosis engages the p55 protein or
MMP-1 (membrane protein palmitoylated 1) in the cas-
pase pathway [20]. Despite a potential neurological role,
our results provided no evidence for a role for this FasL
genetic variant in migraine.
The KCNJ9 SNP (rs2494211) has been previously associ-
ated with type 2 diabetes in Pima Indians [21], and the T
allele of the KCNJ10 SNP (rs1130183) showed a signifi-
cant association with seizure resistance in the common
forms of focal and generalized epilepsy patients, suggest-
ing that this variation is related to general seizure suscep-
tibility in humans [22]. As reported in Table 3, the tested
SNPs contained within the KCNJ9 and KCNJ10 genes
were not significantly associated with migraine or its sub-
types (MA, MO) with chi-square results producing P val-
ues greater than 0.05 for most analyses. However, KCNJ10
genotypic outcomes showed an interesting result (χ2 =
7.65, P = 0.02), that may be worth exploring in a larger,
independent population. Our previous study also
reported no association between another KCNN3gene (a
neuronal small conductance calcium-activated potassium
channel localised close to ATP1A2 on C1q23 region) and
migraine [4]. KCNJ10 codes for one type of G protein acti-
vated inward rectifier potassium (GIRK) type 3 or channel
Kir 3.3. These channels have been previously showed sta-
bly interacting with 3 different metabotropic receptors
(D2 and D4 dopaminergic receptors and the beta 2 adren-
ergic receptor) by co-precipitation in cell culture. The sta-
ble complex formed by G protein-coupled receptors and
Table 4: Chi-squared (χ 2) analysis of all migraine groups against 
controls for the KCNJ10 SNP (rs1130183) polymorphism
Genotypic 
frequencies
Allelic frequencies
Migraine vs Control X2 = 7.65 P = 0.02 X2 = 0.14 P = 0.71
MA vs Control X2 = 5.12 P = 0.08 X2 = 0 P = 0.95
MO vs Control X2 = 1.02 P = 0.59 X2  = 0.42 P = 0.52 
Female Migraine vs Female 
Control
X2 = 5.32 P = 0.07 X2 = 0.03 P = 0.87
Male Migraine vs Male Control X2 = 2.56 P = 0.28 X2 = 0.24 P = 0.62
Total case vs con-
trol
X2 = 0.14 P = 0.713 X2 = 7.65 P = 0.02
Subtype MA vs cont: X2 = 0 P = 0.95 X2 = 5.12 P = 0.08
Subtype MO vs cont X2 = 0.42 P = 0.52 X2 = 1.02 P = 0.59
N Alleles Genotypes
Group (alleles) A G AA AG GG
CACNA1E SNP rs 704326
Migraine 464 384 (83%) 80 (17%) 154 (66%) 76 (33%) 2 (1%) 
Male 142 134 (94.4%) 8 (5.6%) 63 (88.7%) 8 (11.3%) 0
Female 308 240 (77.9%) 68 (22.1%) 89 (57.8%) 62 (40.3%) 3 (1.9%)
MA 276 224 (81%) 52 (19%) 88 (64%) 48 (35%) 2 (1%)
MO 188 160 (85%) 28 (15%) 66 (70%) 28 (30%) 0
Control 424 341 (80%) 83 (20%) 132 (63%) 77 (36%) 3 (1%) 
Male 116 101 (87.1%) 15 (12.9%) 43 (74.1%) 15 (25.9%) 0
Female 308 240 (77.9%) 68 (22.1%) 89(57.8%) 62 (40.3 %) 3 (1.9%)
Total case vs con-
trol
X2 = 1.00 P = 0.6 X2 = 0.81 P = 0.37
Subtype MA vs cont: X2 = 0.06 P = 0.80 X2 = 0.09 P = 0.96
Subtype MO vs cont X2 = 1.92 P = 0.16 X2 = 2.78 P = 0.25
MO, migraine without aura; MA, migraine with aura
Table 3: Distribution of the ATP1A4, CAS Q1, KCNJ9, KCNJ10, and CACNA1E SNPs in migraineurs and controls of original sample Page 6 of 8
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iological relevance [23]. The existence of dopaminergic
hypersensitivity in migraine is recognised on pharmaco-
logical basis [24], and some studies reported a genetic
association between migraine and molecular variations in
DA genes as D2 dopaminergic receptor [25] and D4
dopaminergic receptor [26]. It may be interesting to study
other actors of this pathway and analysing the genes cod-
ing for the regulator of G protein signalling (RGS), more
precisely RGS 7, 4, 21 and 21 genes localised in C1q 23.1–
31.2 region.
From the three other genes tested on chromosome 1,
SNPs were carefully scrutinized and selected to be the
most informative genetic markers for these genes, as no
previous, published, case-control studies had been per-
formed on these genes. The SNPs contained within the
ATP1A4 (rs 6427504) and CASQ1 (rs 3747623) genes
and also located on C1q23, did not show any association
with migraine or its subtypes with P values being greater
than 0.05 (Table 3). The ATP1A4 is a subunit of the
sodium/potassium ATPase gene, which has been recently
associated with a subtype of migraine, FHM [2,27]. How-
ever, several reports studying ATP1A2 polymorphisms did
not find any involvement in MA [28,29], suggesting a dis-
tinct genetic origin for the subtypes of migraine (FHM and
MA). The ATP1A2 gene encodes the catalytic subunit of
ATPase, co-transporter of ions sodium and potassium,
which is abundant in both neurons and astrocytes [30].
This transmembrane protein is localised at the same
region than of the Na+/Ca2+ exchanger in neurons and
astrocytes, demonstrated by immunocytochemistry [31].
This coupled activity of two ion transport systems might
be the origin of the pathogenic mechanism leading
migraine in FHM. Previous report about FHM (type 1), is
caused by mutations contained within the calcium chan-
nel gene CACNA1A (localized at C19p13). CACNA1E
(C1q31) is subunit of R-type voltage-dependent calcium
channel, and the genetic sequence similarities between
CACNA1A and CACNA1E are 61% identical in humans.
SNP (rs 704326) localised within the CACNA1E gene was
investigated in this study but no significant association
was found for this polymorphism in total migraine versus
controls nor in the MA subtype versus controls (Table 3).
This reinforces the theory that FHM and MA are two dif-
ferent genetic entities.
Conclusion
Overall our studies investigating potential migraine can-
didate genes in the chromosome 1q23 and 1q31 regions
did not provide evidence implicating any of the tested var-
iants of the ATP1A4, CASQ, KCNJ9 and 10, FasL,
CACNA1AE genes in migraine. It is possible that other
genetic markers located in these genes and other candi-
date genes from these genomic regions may be implicated
in migraine, but further studies are needed to clarify this
possibility. Furthermore, as the power of an association
study is affected not only by sample size, but other
unknown factors such the strength of the association or
degree of difference between the case and control subjects,
as well as the genetic effect (ie. penetrance) [32], the pos-
sibility of false negative results should not be ruled out.
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Table 5: Distribution of the FasL (CA repeats) in migraineurs and controls of original sample
Alleles 
Alleles N 11 12 13 14 15
Migraine 464 1 (0.2%) 2 (0.4%) 228 (49.1%) 231 (49.8%) 2 (0.4%)
Male 64 1 (1.6%) 0 27 (42.2%) 35 (54.7%) 1 (1.6 %)
Female 400 0 2 (0.5%) 201(50.3%) 196 (49%) 1 (0.3%)
MA 376 1 (0.3%) 2 (0.5%) 190 (50.5%) 182 (48.4% 1 (0.3%)
MO 88 0 0 38 (43.2 %) 49 (55.7%) 1 (1.1%)
Control 552 1 (0.2%) 0 262 (47.5%) 280 (50.7%) 9 (1.6%) 
Male 88 0 0 213 (46.3%) 241 (52.4%) 5 (15.6%)
Female 460 1 (0.2%) 0 47 (53.4%) 39 (44.3 %) 2 (2.3%)
Total case vs 
control
X2 = 5.93 P = 0.204
Subtype MA vs cont: X2 = 7.55 P = 0.109
Subtype MO vs cont X2 = 0.94 P = 0.919
MO migraine without aura, MA migraine with auraPage 7 of 8
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